BioSpace News Archive

Sequana Medical NV, an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, announces that its management team will participate in the following upcoming virtual investor conferences.

CPM device is a treatment modality which continuously and repeatedly moves the joint through a controlled range of motion. Continuous passive motion (CPM) devices are used during first phase of rehabilitation. Continuous passive motion (CPM) devices used in rehabilitation procedure increase the limited movement of joint.

Inspection machines refer to sequence or combination of machines utilized in the inspection of product quality in terms of dimension, leakage, weight, packaging component, and packaging.

Elicio Therapeutics , a private biotechnology company developing a pipeline of potent immunotherapies based on its proprietary lymph node targeting technology, today announced Christopher Haqq , M.D., Ph.D., Elicio’s Executive Vice President, Head of Research and Development, and Chief Medical Officer, will co-lead a workshop

Propanc Biopharma, Inc. (OTCQB: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, announced today that the Company’s Scientific Advisory Board member, internationally recognized cancer expert and Prof. of Human Anatomy and Embryology, Juan Marchal M.D., Ph.D., at the University of Granada, Spain

Neogen Corporation (NASDAQ: NEOG) announced today the launch of Early Warning™ COVID-19 Testing for wastewater.

Existing partnership for manufacture of NVX-CoV2373 expanded to increase production capacity and supply vaccine to the Korean Government

This loan will further support the progress and expansion of OSE Immunotherapeutics’ lead clinical development programs in diseases with high unmet medical needs,

Lysogene, a phase 3 gene therapy platform company targeting central nervous system diseases, reports biomarker data from the ongoing AAVance clinical trial with LYS-SAF302 for the treatment of MPS IIIA presented at the WORLDSymposium™ 2021 by Dr. Michaël Hocquemiller, Head of Non-Clinical Development, during the Late-Breaking Science session held on Friday, February 12, 2021.

Early demonstration of favorable LUMEVOQ® safety profile in human subjects subsequently confirmed in later trials